Edition:
United Kingdom

CTi Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

2.63USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
37,077
52-wk High
$6.42
52-wk Low
$2.61

Select another date:

Tue, Nov 28 2017

BRIEF-CTI Biopharma Corp Says Co Entered Into A Loan And Security Agreement​

* CTI BIOPHARMA CORP - ‍ON NOVEMBER 28, 2017, CTI BIOPHARMA CORP ENTERED INTO A LOAN AND SECURITY AGREEMENT​

BRIEF-CTI BIOPHARMA FILES FOR MIXED SHELF OF UP TO $200 MLN‍​

* CTI BIOPHARMA CORP FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING‍​ Source text: (http://bit.ly/2zo6CPZ) Further company coverage:

BRIEF-CTI Biopharma reports third quarter 2017 financial results

* CTI Biopharma Corp - ‍total revenues for q3 were $1.7 million compared to $4.4 million Source text for Eikon: Further company coverage:

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV, Oct 16 BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

BRIEF-CTI Biopharma appoints Laurent Fischer as new board chairman

* CTI Biopharma appoints Laurent Fischer as new chairman of the board and announces management promotions

BRIEF-CTI Biopharma announces european medicines agency validation of Pacritinib

* CTI Biopharma announces european medicines agency validation of pacritinib marketing authorization application for patients with myelofibrosis who have thrombocytopenia

BRIEF-Stonepine Capital Management LLC reports 7.6 pct passive stake in CTI Biopharma Corp as of June 6, 2017

* Stonepine Capital Management LLC reports 7.6 percent passive stake in cti biopharma corp as of june 6, 2017 - SEC filing Source text - (http://bit.ly/2tycnHF) Further company coverage:

BRIEF-Orbimed Advisors Llc reports 11.6 percent passive stake in CTI Biopharma Corp

* Orbimed Advisors Llc reports 11.6 percent passive stake in CTI Biopharma Corp as of June 9 Source text: (http://bit.ly/2sg61MT) Further company coverage:

Select another date: